Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) in Colorectal Cancer is Associated with an Elderly, Frail Phenotype and Improved Recurrence-Free Survival
- 29 Downloads
Elevated microsatellite alterations at selected tetranucleotides (EMAST) is a poorly investigated form of microsatellite instability (MSI) in colorectal cancer (CRC).
The aim of this study was to investigate the clinicopathological features of EMAST in CRC and its relation to outcome.
A population-based, consecutive cohort of surgically treated stage I–III CRC patients investigated for high-frequency MSI (MSI-H) and EMAST. Clinicopathological differences were reported as odds ratios (OR) and survival was presented as hazard ratios (HR) with 95% confidence intervals (CIs).
Of 161 patients included, 25% were aged > 79 years. There was a large overlap in the prevalence of EMAST (31.7%) and MSI-H (27.3%) [82.4% of EMAST were also MSI-H]. EMAST had the highest prevalence in the proximal colon (OR 15.9, 95% CI 5.6–45.1; p < 0.001) and in women (OR 4.1, 95% CI 1.9–8.6; p < 0.001), and were poorly differentiated (OR 5.0, 95% CI 2.3–10.7; p < 0.001). Compared with EMAST-negative patients, EMAST-positive patients were older (median age 77 vs. 69 years; p < 0.001), leaner (median weight 67.5 vs. 77 kg; p = 0.001), had significantly higher rates of hypoalbuminemia (24% vs. 6%; OR 2.3, 95% CI 1.5–3.6; p = 0.002) and anemia (45% vs. 20%; OR 3.3, 95% CI 1.6–6.8; p = 0.001), and had elevated preoperative C-reactive protein (CRP) levels (51% vs. 34%; OR 1.9, 95% CI 1.0–3.9; p = 0.046). Improved recurrence-free survival was found in both MSI-H and EMAST subtypes. In multivariable analysis, node status (pN +), together with elevated CRP and MSI-positive, were the strongest prognostic factors for recurrence-free survival.
EMAST in CRC is associated with an older, leaner, and frailer phenotype with a lower risk of recurrence. The relevance of, and putative mechanisms to, EMAST warrants further investigation.
The QiaCUBE instrument was generously donated by the Hartman Family Fund.
This study was funded by the Folke Hermansen Cancer Fund, an unrestricted grant from the Mjaaland Foundation, and from the University Fund at the University of Stavanger.
Martin M. Watson, Arezo Kanani, Dordi Lea, Ramesh B. Khajavi, Jon Arne Søreide, Hartwig Kørner, Hanne R. Hagland, and Kjetil Søreide declare no conflicts of interest.
- 13.Søreide K, Watson MM, Lea D, Nordgård O, Søreide JA, Hagland HR. Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis. J Transl Med. 2016;14(1):192.CrossRefGoogle Scholar
- 14.Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual 7th ed: colon and rectum. 7th ed. New York: Springer; 2010.Google Scholar
- 21.Chow WB, Rosenthal RA, Merkow RP, Ko CY, Esnaola NF. Optimal preoperative assessment of the geriatric surgical patient: a best practices guideline from the American College of Surgeons National Surgical Quality Improvement Program and the American Geriatrics Society. J Am Coll Surg. 2012;215(4):453–66.CrossRefGoogle Scholar
- 37.Chen MH, Chang SC, Lin PC, et al. Combined microsatellite instability and elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) might be a more promising immune biomarker in colorectal cancer. Oncologist. https://doi.org/10.1634/theoncologist.2019-0171